The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,703.00
Bid: 4,702.00
Ask: 4,706.00
Change: 54.00 (1.16%)
Spread: 4.00 (0.085%)
Open: 4,687.00
High: 4,716.00
Low: 4,632.00
Prev. Close: 4,649.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

20 Apr 2018 11:14

RNS Number : 6351L
Croda International PLC
20 April 2018
 

The following amendment has been made to the Directorate Change announcement released on 20 April 2018 at 07:00 under RNS No 5187L.

 

Name amended from Robert to Roberto in the first paragraph.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

20 April 2018

 

 

Croda International Plc

 

 

Appointment of Non-Executive Directors - Board succession planning

 

 

The Board of Croda International Plc is pleased to announce the appointment of Roberto Cirillo and Jacqui Ferguson as non-executive directors. Roberto will join the Board with effect from 26 April 2018 and Jacqui will join with effect from 1 September 2018.

 

These appointments strengthen the Board's skills and experience in the areas of strategy, operations, international/emerging markets and digitalisation.

 

Roberto has worked in a number of international roles over the last 20 years, most recently as CEO of Optegra, the international eye healthcare company. Before that he was at Sodexo, where he played a critical role in the company's transformation and growth, working in a variety of roles, including in strategy and later as Group COO and as Country CEO of their French business. Prior to that Roberto worked as a consultant at Mckinsey & Company across many different areas and countries.

 

Jacqui has almost 30 years' experience in international roles in the technology sector. She held many senior operating roles at Hewlett Packard, including SVP & General Manager of HP's Enterprise Services Division in Europe whose business was to deliver digital and technology enabled transformations for enterprises. She was also Chief of Staff at Hewlett Packard working with the Chairman and CEO focused on a new company strategy and transformation. Prior to Hewlett Packard Jacqui worked for Electronic Data Systems, acquired by HP in 2008, and KPMG. Jacqui is currently a non-executive director of Wood Plc.

 

On joining the Board, both Jacqui and Roberto will also be appointed to the Audit, Nomination and Remuneration Committees. 

 

Anita Frew, Chairman of Croda International Plc, said,

 

"Both appointments will be of enormous benefit to the Croda Board, supporting our strategic plans to connect more dynamically to customers through the use of technology and helping customers transition to more sustainable ingredients. Roberto brings with him a wealth of international experience in operations and strategy and Jacqui a deep knowledge of digital as well as experience in operating in emerging markets. The appointments will also bring greater diversity to the Board in terms of gender, tenure, nationality and experience. We are delighted to welcome them both to the Croda Board.

 

"As previously announced, Nigel Turner will be retiring from the Board on 26 April 2018, at which time Alan Ferguson will take on the role of Senior Independent Director.

 

"Steve Williams will have served on the Board for nine years in 2019. In preparation for his retirement next year, Helena Ganczakowski will take over as Chairman of the Remuneration Committee with effect from 26 April 2018. This will give Helena a good period as Chairman to prepare for the Committee's review of the Company's remuneration policy at the end of the year. Helena has been a member of the Remuneration Committee since 1 February 2014.

 

"All these changes to the Board are consistent with the Board's approach to succession planning."

 

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.

 

 

 

 

Enquiries:

 

Shareholders: Conleth Campbell, VP Investor Relations +44 1405 860 551

 

Press: Charlie Armistead, Teneo Blue Rubicon +44 203 603 5220

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGZDGGZGRZM
Date   Source Headline
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion
29th Mar 20227:00 amRNSInvestor seminar
22nd Mar 20226:14 pmRNSAnnual Financial Report
22nd Mar 20224:49 pmRNSDirector/PDMR Shareholding
16th Mar 20225:21 pmRNSDirector/PDMR Shareholding
16th Mar 20225:20 pmRNSDirector/PDMR Shareholding
16th Mar 20225:19 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:13 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:04 pmRNSDirector/PDMR Shareholding
16th Mar 20225:03 pmRNSDirector/PDMR Shareholding
15th Mar 202211:24 amRNSDirector/PDMR Shareholding
11th Mar 20222:25 pmRNSDirector/PDMR Shareholding
10th Mar 20221:10 pmRNSDirector/PDMR Shareholding
3rd Mar 202211:27 amRNSDirector/PDMR Shareholding
1st Mar 20227:00 amRNSResults for the year ended 31 December 2021
11th Feb 20222:26 pmRNSDirector/PDMR Shareholding
25th Jan 202210:47 amRNSHolding(s) in Company
17th Jan 20222:18 pmRNSHolding(s) in Company
11th Jan 20223:56 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.